Partnership Implementation of NIPT in a Government-Funded Health System: Operational Requirements and Impact on Care

December 06, 2016

Partnership Implementation of NIPT in a Government-Funded Health System: Operational Requirements and Impact on Care

Genome Webinar

Join or Log in for Access

This content is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

This webinar discusses a partnership model for noninvasive prenatal testing that enabled LifeLabs Genetics, a genetic testing lab based in Toronto, Ontario, to implement NIPT in house.

LifeLabs implemented on-site testing of the Natera Panorama test service in October 2015 in Toronto, where funding is provided for chromosome aneuploidy testing under selected high-risk criteria set out by the Ontario Ministry for Health and Long-Term Care. Patients have the option of self-pay if they do not meet risk criteria. On-site testing capacity includes microdeletions as of July 2016.

Breaking News

Featured White Papers

High-Throughput Detection of SARS-CoV-2 Using COVIDSeq NGS: A GenomeWeb eCase Study Transcript

NGS-Based Target Capture for SARS-CoV-2 Detection and Characterization

Feb

22

Featured Webinar

Trends in Variant Interpretation Workflows: Expert Insights to Advance NGS Oncology Profiling

Please join GenomeWeb and Qiagen for an online roundtable discussion where a panel of experts will review challenges and opportunities around genomic variant interpretation workflows in the field of oncology.

Feb

23

Featured Webinar

After the Surge: Driving Sample Processing Efficiency of Coronavirus Samples

As the world continues to contend with coronavirus and a surge in the infection rate, labs are required to run more samples than ever before.

Feb

24

Featured Webinar

Case Study: Rapid Development and Manufacturing Scaleup of a Point-of-Care COVID-19 Test

Developing a fully integrated consumable cartridge for an automated diagnostic platform is a significant challenge. More challenging still is developing such a cartridge in response to a deadly global virus pandemic amid market uncertainty and extraordinary time constraints.

Menu